Slower growth in Swiss economy will impact pharma, says BMI

It is the view that the Swiss economy will record slower growth in 2012, says Business Monitor International in a new report on the country’s pharmaceutical and health care sector, noting that this may lead to the implementation of more austerity measures which will impact the publicly funded pharmaceuticals and health care sector.

Prescription drug spending in Switzerland accounted for 76% of total drug spending in 2010 and public expenditure on health accounted for 58% of total spending on health care. The study also reveals Swiss consumers are paying 300 million francs too much each year for prescription medicines.

Headline expenditure projections